Drugs.com - Clinical Trials

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Tokyo and Basking Ridge, NJ – (June 18, 2025) – The first patient has been dosed in the IDeateProstate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (IDXd) versus docetaxel in patients with...

Jun 19, 2025 - 07:00
 0
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
Tokyo and Basking Ridge, NJ – (June 18, 2025) – The first patient has been dosed in the IDeateProstate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (IDXd) versus docetaxel in patients with...
Read More

Tags:

Previous Article

Spain Recalls Four Cosmetics Brands Over Manufacturing Violations

Next Article

FDA Adds Warning About Serious Risk of Heat-Related Complications With Antinause...

Related Posts

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics Reports Positive Results from the ENL...

Jun 4, 2025  0

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Global Phase III Trials Demonstrate That Nerandomilast ...

May 20, 2025  0

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Genentech and Roche Present Novel Therapeutic and Diagn...

May 12, 2025  0